## Studies that fit the criteria

### Haris's Studies 

GSE138531: 3 stenotic vs 3 sclerotic human aortic valve samples. Do one as a control and one as treatment. 

GSE141910: Left ventricular transcriptomes of non-failing healthy donors, Peripartum cardiomyopathy (PPCM), Hypertrophic cardiomyopathy (HCM) and Dilated cardiomyopathy (DCM) samples.

GSE143148: Differentiated medium vs full medium. (RNA Samples only).

GSE55492: Control vs Calcified tricuspid aortic valve.

GSE60292: Unstimulated control cardiomyocytes vs ET-1 stimulated cardiomyocytes.

GSE65446: Controls vs heart mRNA profiles from dilated cardiomyopathy diagnosed patients who had undergone heart transplant.

GSE65705: 16 ST-segment elevation myocardial infarction (STEMI), 16 non-STEMI (NSTEMI), and 2 controls.

GSE67844: Cardiomyoctyes treated with siRNA knockdown (scrambled control, PANCR, PITX2c) in triplicate and RNA and smallRNAs extracted for sequencing.

GSE76717: Calcified tricuspid aortic valves vs controls.

GSE83410: Profiling AGO2-associated RNAs in cardiac tissues (6 samples differing etiologies). Continous variable.

GSE85565: Control vs TCF21 overexpression.

GSE36759: Right ventricular small RNA-seq profiles from 22 patients with Tetralogy of Fallot and small RNA-seq profiles from the left and right ventricle of 4 healthy unaffected individuals.

GSE36761: Right ventricular mRNA-seq profiles from 22 patients with Tetralogy of Fallot and small RNA-seq profiles from the left and right ventricle of 4 healthy unaffected individuals. 

GSE89714: Control vs heart tissue of hypertrophic cardiomyopathy patients.

### Chelsia's Studies

GSE95120: Control vs Cardiac stromal cells from Arrhythmogenic cardiomyopathy patients.

GSE95390: Human induced pluripotent stem cells to generate cardiac progenitor cells.

GSE96975: Control(basal) vs Cardiac fibroblasts treated with IL11 vs Cardiac fibroblasts treated with TGFB1.

GSE98941: Control vs polyI:C treated cardiac progenitors vs TGFbeta treated cardiac progenitors.

GSE99321: Controls vs LV of pediatric idiopathic dilated cardiomyopathy patients.

GSE108157: LV samples - ischemic vs non-ischemic heart failure.

GSE44461: non-silencing control versus TCF21 knockdown.

GSE120567: Myocarditis vs DCM patients.

GSE120852: Left and Right Ventricles of 15 individuals, 5 control, 5 left-sided Heart Failure, 5 bi-ventricular Heart Failure (WIPI1).

GSE121559: Familial control vs human induced pluripotent stem cell-derived cardiomyocytes from a cardiomyopathy patient. 

GSE46224: RNA and non-coding RNA transcriptome profiling in human failing and non-failing control hearts. 5 groups of samples: NF, ICM, NICM, ICM+LVAD, NICM+LVAD

GSE128188: Control vs Atrial fibrillation.

GSE48166: Control vs Ischemic cardiomyopathy.

## Studies that do not fit the criteria

GSE138837: Less than 3 replicates.

GSE126488: Study explores human embryo transcriptomics datasets and expression of transcripts for insuling and insulin growth factor 1 (IGF1) receptors.

GSE139335: Study explores neuroendocrine prostate cancer.

GSE139685: Study explores keratinocytes in the skin.

GSE53080: Less than 3 replicates.

GSE53296: Less than 3 replicates.

GSE55939: Study explores Turner syndrome.

GSE56648: Less than 3 replicates.

GSE57012: Study explores psoriasis.

GSE57896: Study explores white-to-brown metabolic conversion of human adipocytes.

GSE60217: Less than 3 replicates.

GSE63055: Study explores Williams Beuren Syndrome (WBS) and 7q microduplication syndrome (7dupASD).

GSE63161: Less than 3 replicates.

GSE64942: Study explores germ cells.

GSE65523: Less than 3 replicates.

GSE65752: Study explores Epstein-Barr virus.

GSE65761: Less than 3 replicates.

GSE67488: Less than 3 replicates.

GSE67489: Less than 3 replicates.

GSE70668: Study explores oncogene-induced senescence.

GSE71613: Less than 3 replicates.

GSE71710: Less than 3 replicates.

GSE72379: Less than 3 replicates.

GSE72696: Less than 3 replicates.

GSE73210: Less than 3 replicates.

GSE73370: Study explores breast cancer.

GSE73478: Study explores immune response to bacterial macrophages (miRNA). 

GSE73502: Study explores immune response to bacterial macrophages (mRNA).

GSE74142: Less than 3 replicates.

GSE74235: Hydroxychloroquine inhibits responses to group A streptococcus that can lead to development of rheumatic heart disease.

GSE74941: Less than 3 replicates.

GSE74716: Less than 3 replicates.

GSE74798: Study explores prostate cancer cells.

GSE76712: Lacks control group.

GSE77784: Study not relevant to heart disease.

GSE80333: Study explores breast cancer cells.

GSE81046: Study explores immune response to pathogens.

GSE81254: Study explores samples of ocular tissue.

GSE32689: Less than 3 replicates.

GSE81608: Study explores pancreatic islet cells.

GSE81809: Sample description unclear.

GSE83245: Study explores rectal mucosal transcriptome.

GSE84536: Study explores liver tissue effected by dengue hemorrhagic fever.

GSE84814: Study explores glucose effects on early heart development.

GSE85623: Less than 3 replicates.

GSE86316: Study explores breast cancer cells.

GSE87626: Study explores breast cancer cells.

GSE89843: Study explores lung cancer. 

GSE89972: Less than 3 replicates.

GSE92447: Less than 3 replicates.

GSE92616: Less than 3 replicates.

GSE92724: Study explores diabetes (mentions heart disease).

GSE93235: Study explores HeLa cells.

GSE93740: Study explores breast cancer.

GSE94533: Study explores ovarian cancer.

GSE95155: Study not relevant to heart disease.

GSE85632: Less than 3 replicates.

GSE98206: Study explores lymphocytic leukemia.

GSE99349: Study explores cocaine use disorder.

GSE100075: Study explores breast cancer.

GSE101788: Study explores leukemia.

GSE101913: Study not relevant to heart disease.

GSE102934: Study not relevant to heart disease.

GSE103327: Study explores hepatocellular carcinoma. 

GSE107923: Less than 3 replicates.

GSE108763: Study not relevant to heart disease.

GSE113117: Less than 3 replicates.

GSE115099: Study explores skin disease.

GSE116744: Study explores breast cancer.

GSE45722: Less than 3 replicates.

GSE121578: Less than 3 replicates.

GSE121699: Less than 3 replicates.

GSE121893: Less than 3 replicates.

GSE47399: Study not relevant to heart disease.

GSE49716: Less than 3 replicates.

## Contrasts
SRP026208:left ventricular control myocardial samples versus ischemic cardiomyopathy (ICM) sample: control; SRX312124, SRX312125, SRX312126,	SRX312127, SRX312128, SRX312129, SRX312130,	SRX312131, SRX312132, SRX312133, SRX312134, SRX312135, SRX312136, SRX312137,	SRX312138, SRX312139: ICM samples; SRX312140, SRX312141,	SRX312142, SRX312143, SRX312144, SRX312145,	SRX3121246,	SRX312147, SRX312148,	SRX312149, SRX312150,	SRX312151, SRX312152, SRX312153, SRX312154,	SRX312155;

SRP188219:control sinus rhythm versus permanent atrial fibrillation performed on the left and right atrial appendages:control; 	SRX5509125, 	SRX5509126, 	SRX5509127,	SRX5509128,	SRX5509129,	SRX5509130,	SRX5509131,	SRX5509132,	SRX5509133,	SRX5509134:atrial fibrillation; 	SRX5509135,	SRX5509136,	SRX5509137,	SRX5509138,	SRX5509139,	SRX5509140,	SRX5509141,	SRX5509142,v,	SRX5509143,	SRX5509144; sex

SRP188219:sinus rythm in left atrium versus right atrium:left atrium; SRX5509125, SRX5509127, SRX5509129, SRX5509131, SRX5509133:right atrium; SRX5509126, SRX5509128, SRX5509130, SRX5509132, SRX5509134; sex

SRP188219:atrial fibrillation in left atrium versus right atrium:left atrium;SRX5509135, SRX5509137, SRX5509139, SRX5509141, SRX5509143:right atrium; SRX5509136, SRX5509138, SRX5509140, SRX5509142, SRX5509144; sex 

SRP188219: sinus rythm in the left atrium versus atrial fibrilation in the left atrium:sinus rythm;	SRX5509127, SRX5509129,	SRX5509131,	SRX5509132,	SRX5509133:atrial fibrillation;	SRX5509135,	SRX5509137,	SRX5509139,	SRX5509141,	SRX5509142; sex

SRP188219:sinus rythm in the right atrium versus atrial fibrilation in the right atrium: sinus rythm; SRX5509126, SRX5509128, SRX5509130, SRX5509132, SRX5509134:atrial fibrillation; SRX5509136, SRX5509138, SRX5509140, SRX5509141, SRX5509142; sex

SRP021193:human non-failing (NF) in left ventricle apex tissue versus ischemic cardiomyopathy (ICM) using RNASeq:NF; SRX268708, SRX268709, SRX268710, SRX268711, SRX268712, SRX268713, SRX268714, SRX268715:ICM; SRX268716, SRX268717, SRX268718, SRX268719, SRX268720, SRX268721, SRX268722, SRX268723; LVAD support

SRP021193:human non-failing (NF) in left ventricle apex tissue versus non-ischemic cardiomyopathy (NICM) using RNASeq:NF; SRX268708, SRX268709, SRX268710, SRX268711, SRX268712, SRX268713, SRX268714, SRX268715:NICM; 	SRX268724, SRX268725,	SRX268726,	SRX268727,	SRX268728,	SRX268729,	SRX268730,	SRX268731; LVAD support

SRP021193:ischemic cardiomyopathy (ICM) versus ischemic cardiomyopathy post left ventricular assist device (ICM+LVAD):ICM; SRX268716, SRX268717, SRX268718, SRX268719, SRX268720, SRX268721, SRX268722, SRX268723:ICM+LVAD; SRX268732, SRX268733, SRX268734, SRX268735, SRX268736, SRX268737, SRX268738, SRX268739; LVAD support

SRP021193:non-ischemic cardiomyopathy(NICM) versus non-ischemic cardiomyopathy post left ventricular assist device (NICM+LVAD):NICM; SRX268724, SRX268725,	SRX268726,	SRX268727,	SRX268728,	SRX268729,	SRX268730,	SRX268731:NICM+LVAD; SRX268740, SRX268741,SRX268742, SRX268743, SRX268744, SRX268745, SRX268746,	SRX268747

SRP166274:human induced pluripotent stem cell-derived cardiomyocytes from a familial control versus cardiomyopathy:familial control;	SRX4910761,	SRX4910762,	SRX4910763: cardiomyopathy;	SRX4910764,	SRX4910765,	SRX4910766;

SRP163478:right ventricle non-failing (NF) tissue versus left ventricle heart failure (LV-HF):NF;	SRX4799399,	SRX4799401,	SRX4799402,	SRX4799403,SRX4799404:LV-HF;SRX4799404,SRX4799405,SRX4799406,SRX4799407,SRX4799408;

SRP163478:right ventricle non-failing (NF) tissue versus biventricular heart failure (BiV-HF):NF;	SRX4799399,	SRX4799401,	SRX4799402,	SRX4799403,SRX4799404:BiV-HF;SRX4799409,SRX4799410,SRX4799411,SRX4799412,SRX4799413;

SRP163478:right ventricle LV-HF versus BiV-HF:LV-HF;SRX4799404,SRX4799405,SRX4799406,SRX4799407,SRX4799408:BiV-HF;SRX4799409,SRX4799410,SRX4799411,SRX4799412,SRX4799413;

SRP163478:left ventricle non-failing (NF) tissue versus left ventricle heart failure (LV-HF):NF;	SRX4799414,	SRX4799415,	SRX4799416,	SRX4799417,	SRX4799418:LV-HF;	SRX4799419,	SRX4799420,	SRX4799421,	SRX4799422,	SRX4799423;

SRP163478:left ventricle non-failing (NF) tissue versus biventricular heart failure (BiV-HF):NF;	SRX4799414,	SRX4799415,	SRX4799416,	SRX4799417,	SRX4799418:BiV-HF;SRX4799424,SRX4799425,SRX4799426,SRX4799427,SRX4799428;

SRP163478:left ventricle LV-HF versus BiV-HF:LV-HF;	SRX4799419,	SRX4799420,	SRX4799421,	SRX4799422,	SRX4799423:BiV-HF;SRX4799424,SRX4799425,SRX4799426,SRX4799427,SRX4799428;

SRP163478:patients with a non-inflammatory dilated cardiomyopathy (DCM) versus patients with acute myocarditis:DCM;	SRX4744907,	SRX4744908,	SRX4744909,	SRX4744910,SRX4744911,	SRX4744912,	SRX4744913,	SRX4744914,	SRX4744915,	SRX4744916,	SRX4744917:myocarditis;SRX4744918,SRX4744919,SRX4744920,SRX4744921,SRX4744922;age

SRP018779:non-silencing control versus TCF21 knockdown:non-silencing;	SRX243750,	SRX243751,	SRX243752:TCF21;SRX243753,SRX243754,SRX243755;

SRP126861:left ventricle samples in non-ischemic cardiomyopathy (NICM) versus ISCH:NICM;SRX3474755,SRX3474756,SRX3474758,SRX3474760,SRX3474761,SRX3474762:ISCH;	SRX3474757,SRX3474759,SRX3474763,	SRX3474764,SRX3474765; sex, race

SRP108065:control versus left ventricle of pediatric idiopathic dilated cardiomyopathy patients:control;SRX2858506,SRX2858508,	SRX2858509,	SRX2858511,SRX2858512,	SRX2858513,	SRX2858517:idopathic dilated cardiomyopathy;SRX2858505,SRX2858507,	SRX2858510,	SRX2858514,	SRX2858515,SRX2858516,	SRX2858518;

SRP107288:Control versus polyI:C treated cardiac progenitors:control;SRX2827481,SRX2827482,	SRX2827483:polyI:C;SRX2827487,SRX2827488,SRX2827489;

SRP107288:Control versus TGFbeta treated cardiac progenitors:control;SRX2827481,SRX2827482,	SRX2827483:TGFbeta;SRX2827484,SRX2827485,	SRX2827486;

SRP107288:polyI:C treated cardiac progenitors versus TGFbeta treated cardiac progenitors:polyI:C;SRX2827487,SRX2827488,SRX2827489:TGFbeta;SRX2827484,SRX2827485,	SRX2827486;

SRP102374:Control basal versus cardiac fibroblasts treated with IL11:control;SRX2664166,	SRX2664168,	SRX2664170,SRX2664172,SRX2664174,SRX2664176,	SRX2664178,SRX2664180,SRX2664182,SRX2664184:IL11;SRX2664167,SRX2664169,SRX2664171,	SRX2664173,SRX2664175,SRX2664177,SRX2664179,SRX2664181,SRX2664183,SRX2664185;

SRP102374:Control basal versus cardiac fibroblasts treated with TGFB1:control;SRX2664166,	SRX2664168,	SRX2664170,SRX2664172,SRX2664174,SRX2664176,	SRX2664178,SRX2664180,SRX2664182,SRX2664184:TGFB1;SRX2664186,SRX2664187,SRX2664188,SRX2664189;

SRP102374:cardiac fibroblasts treated with IL11 versus cardiac fibroblasts treated with TGFB1: IL11;SRX2664167,SRX2664169,SRX2664171,	SRX2664173,SRX2664175,SRX2664177,SRX2664179,SRX2664181,SRX2664183,SRX2664185:TGFB1;SRX2664186,SRX2664187,SRX2664188,SRX2664189;

SRP100748:human induced pluripotent stem cells(hiPSCs) versus DMSO treated hiPSCs:hiPSCs;	SRX2592092,	SRX2592093,SRX2592094,SRX2592095:DMSO;SRX2592100,SRX2592101,SRX2592102,SRX2592103;

SRP100748:human induced pluripotent stem cells(hiPSCs) versus ISX-9 treated hiPSCs:hiPSCs;	SRX2592092,	SRX2592093,SRX2592094,SRX2592095:ISX-9;SRX2592096,SRX2592097,SRX2592098,SRX2592099;

SRP100748:DMSO treated hiPSCs versus ISX-9 treated hiPSCs:DMSO;SRX2592100,SRX2592101,SRX2592102,SRX2592103:ISX-9;SRX2592096,SRX2592097,SRX2592098,SRX2592099;

SRP100426:control vs cardiac stromal cells from arrhythmogenic cardiomyopathy patients(ACM):control;SRX2578750,SRX2578751,SRX2578752:ACM;SRX2578747,SRX2578748,SRX2578749;sex
